VCA
SRPT icon

Verdence Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Verdence Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,000
Closed -$134K – 533
2021
Q4 		$134K Buy
2,000
+1,000
+100% +$85.5K 0.02% 485
2021
Q3 		$22K Buy
+1,000
New +$77K ﹤0.01% 492

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Verdence Capital Advisors's SRPT Position: Q2 2023 in Review

Verdence Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 3,651 shares — an estimated $503K sold.

Verdence Capital Advisors first reported a position in SRPT in Q3 2020 and held it in 11 quarters. The position peaked at $1.05M in Q3 2020. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • Verdence Capital Advisors reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Verdence Capital Advisors sold 3,651 Sarepta Therapeutics shares in Q2 2023, an estimated $503K.
  • Verdence Capital Advisors first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 11 quarters.
  • Verdence Capital Advisors's Sarepta Therapeutics position peaked at $1.05M in Q3 2020.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Verdence Capital Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.